Bmc Neurosci
-
Alzheimer's Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of dementia in the aging population for which limited therapeutical options are available. These disorders are associated with Tau accumulation. We have previously shown that Cerebrolysin™ (CBL), a neuropeptide mixture with neurotrophic effects, ameliorates the behavioral deficits and neuropathological alterations in amyloid precursor protein (APP) transgenic (tg) mouse model of AD by reducing hyper-phosphorylated Tau. CBL has been tested in clinical trials for AD, however it's potential beneficial effects in FTLD are unknown. For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy. Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically. ⋯ These results suggest that the ability of CBL to ameliorate neurodegenerative pathology in the tauopathy model may involve reducing accumulation of hyper-phosphorylated Tau and reducing alterations in mitochondrial biogenesis associated with Tau.
-
The human brain is frequently exposed to individual faces across a wide range of different apparent sizes, often seen simultaneously (e.g., when facing a crowd). Here we used a sensitive and objective fast periodic visual stimulation approach while recording scalp electroencephalogram (EEG) to test the effect of size variation on neural responses reflecting individual face discrimination. ⋯ Stimulus size variation is an important manipulation to isolate the contribution of high-level visual processes to individual face discrimination. Nevertheless, even for relatively small stimuli, high-level individual face discrimination processes in the right occipito-temporal cortex remain sensitive to stimulus size variation.